Production (Stage)
Bellicum Pharmaceuticals, Inc.
BLCM
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 0.53% | -72.58% | -75.68% | -75.81% | -75.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.53% | -72.58% | -75.68% | -75.81% | -75.81% |
| Cost of Revenue | -9.02% | 26.25% | 18.01% | -3.45% | -27.50% |
| Gross Profit | 9.77% | -63.82% | -55.72% | -22.37% | 13.90% |
| SG&A Expenses | 16.30% | 6.16% | -11.63% | -18.45% | -35.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.45% | 21.53% | 11.20% | -6.89% | -29.33% |
| Operating Income | 3.69% | -46.66% | -35.84% | -10.64% | 20.01% |
| Income Before Tax | -37.74% | -269.61% | -324.58% | -157.30% | -348.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.75% | -269.64% | -324.62% | -157.32% | -348.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.75% | -269.64% | -324.62% | -157.32% | -348.13% |
| EBIT | 3.69% | -46.66% | -35.84% | -10.64% | 20.01% |
| EBITDA | 3.64% | -46.92% | -36.19% | -11.07% | 19.22% |
| EPS Basic | -61.95% | -575.09% | -264.86% | 26.61% | -139.99% |
| Normalized Basic EPS | -62.00% | -930.51% | -362.31% | 19.77% | -132.59% |
| EPS Diluted | -59.21% | -515.94% | -241.49% | 26.91% | -141.61% |
| Normalized Diluted EPS | -61.60% | -905.68% | -356.59% | 19.95% | -133.18% |
| Average Basic Shares Outstanding | 14.06% | 41.00% | 84.76% | 168.28% | 183.78% |
| Average Diluted Shares Outstanding | 13.95% | 40.69% | 84.23% | 167.17% | 182.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |